What NMX Research & Solutions does

NMX Research and Solutions Inc. is a private Contract Research Organization (CRO) founded in 2014 and headquartered in Laval, Quebec, with additional operations in Boston, Massachusetts. The firm specializes in Fragment-Based Drug Discovery (FBDD) and biophysical screening technologies, serving small/mid-size biotech and large pharmaceutical clients engaged in early-stage drug discovery, alongside academic collaborators. Core service lines include a Fragment-Based Lead Discovery (FBLD) platform, an orthogonal Biophysics Platform, Target Production across E. coli/insect/human/cell-free systems, Med-Chem Enablement for hit-to-lead optimization, and Computational Chemistry services. Two proprietary sub-brands anchor routine NMR data delivery: uNMR\u00ae (same-day NMR with courier pickup, Boston since 2016 and Montreal since 2020) and mi-NMR\u00ae (mail-in NMR with global reach).

Underlying technology centers on NMR spectroscopy combined with orthogonal biophysics, integrating proprietary curated 1H and 19F fragment libraries, isotope-labeled protein production (15N, 13C, 19F, 2H, ILV(A) selective labeling), non-deuterated buffer protocols that cut reagent cost, proprietary aggregation/behavior analytics, and in-house crystallography for structural confirmation. The FBLD platform is differentiated by addressing common pitfalls in fragment screening through early compound behavior characterization rather than screening volume alone.

NMX generates revenue on a fee-for-service contract research basis, with quote-based pricing, sales-led direct outreach, active participation in industry conferences (SLAS, FBLD, MOOT NMR, PSDI, PANIC, RNA Canada), and marketplace listings on scientist.com and Science Exchange. The firm also participates in funded consortia (notably the $13.85M FACS-funded Consortium Acuit\u00e9-QC with Universit\u00e9 de Sherbrooke, Mila, IRIC, INRS, and CHU Sainte-Justine) and maintains academic collaborations with Harvard Medical School, INRS, the Broad Institute, University of Minnesota, and Remix Therapeutics, including a joint post-doctoral program with INRS.

Name

NMX Research & Solutions

Legal name

NMX Research and Solutions Inc.

Website

https://nmxresearch.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

NMX Research & Solutions is a Contract Research Organization specializing in Fragment-Based Drug Discovery and biophysical screening, serving small/mid biotech, large pharma, and academic institutions with NMR spectroscopy, proprietary curated fragment libraries, and integrated hit-to-lead services from Laval, Quebec and Boston.

Ownership category

akta.pro rank

Product category

Contract Drug Discovery Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)

akta.pro secondary industries

Material Characterization & Spectroscopy (NMR/FTIR/MS) (HLAGADAK), Clinical Trial Site Operations & Study Coordination (HLAGACAE)

Keywords

• Contract research services
• NMR spectroscopy services
• Fragment-based drug discovery
• Biophysical screening
• Drug discovery research

Headquarters

HQ city

Laval

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Contract Research Services: Fee-for-service contract research organization providing NMR spectroscopy, biophysical screening, fragment-based lead discovery, target production, medicinal chemistry, and computational chemistry services to biotech and pharmaceutical clients.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

NMX Research & Solutions is a Contract Research Organization providing fee-for-service NMR spectroscopy and biophysical screening for early-stage drug discovery. Its core offerings integrate a Fragment-Based Lead Discovery (FBLD) platform built on proprietary curated fragment libraries and orthogonal biophysical methods with remote NMR data acquisition services (uNMR® and mi-NMR®), target protein production, medicinal chemistry, and computational chemistry support.

Product overview

NMX Research & Solutions operates as a Contract Research Partner offering an integrated biophysics and Fragment-Based Lead Discovery (FBLD) platform for early-stage drug discovery. The portfolio consists of a core Biophysics Platform paired with proprietary Fragment-Based Lead Discovery services, supported by specialized NMR service offerings (uNMR® and mi-NMR®) for data acquisition. Additional service lines include Target Production (spanning expression systems from E. coli to cell-free and human cells), Med-Chem Enablement (medicinal chemistry and hit-to-lead optimization), and Computational Chemistry (docking, virtual screening, structure-based drug design). The integrated workflow connects Curated Fragment Libraries with NMR screening, binding studies, Kd determination, and computational analysis to deliver compounds from initial hit to lead optimization.

Differentiator

Problem solved

Functional benefit

Brands

• uNMR®: Same-day NMR data acquisition service offering a wide range of 1D and 2D NMR experiments for medicinal chemists, including courier pickup and secure data delivery.
• mi-NMR®

Products and services

• Fragment-Based Lead Discovery (FBLD) A comprehensive fragment-based drug discovery service for biotech and pharmaceutical clients that integrates proprietary curated fragment libraries with NMR spectroscopy and orthogonal biophysical methods to identify and advance hits to lead candidates.
• Biophysics Platform A biophysical characterization service for biotech and pharma programs that applies orthogonal methods (NMR-based ligand binding studies, Kd and stoichiometry determination, compound behavior analysis, target enablement, and binding site identification) to assess ligand-protein binding, compound behavior, protein stability, and target pockets.
• uNMR® Same-day remote NMR data acquisition service for medicinal chemists and biotech/pharma clients, offering a wide range of 1D and 2D NMR experiments with courier pickup and secure data delivery, operational in Boston since 2016 and Montreal since 2020.
• mi-NMR® Mail-in NMR data acquisition service that lets researchers send samples via courier and receive multi-nuclei, multi-dimensional NMR results, making NMR accessible to clients anywhere in the world.
• Target Production Recombinant protein production service for biotech and pharma clients using E. coli, baculovirus/insect cell, human cell, and cell-free expression systems, covering expression, purification, complex production, and characterization, including isotope labeling strategies.
• Med-Chem Enablement Medicinal chemistry enablement service for drug discovery teams, providing primary structure verification, early analoging, and hit-to-lead optimization through an NMR-based Kd-SAR (structure-activity relationship) cycle.
• Computational Chemistry In silico drug design service for biotech and pharma clients covering molecular docking, virtual screening of compound libraries, and structure-based drug design with pharmacophore identification to support compound prioritization and design hypotheses.

Quantifiable outcome

• Detects and flags problematic aggregating compounds early in discovery, avoiding misleading structure-activity relationships and potential clinical trial failures
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature9 records

Partnerships

17 partnerships are on record, tiered core, flagship and minor.

• Molecular Forecaster Inc. (MFI)coreStrategic or Co-development Partner · 19 December 2023Strategic partnership to expand hypothesis-driven drug design services for preclinical drug discovery. The collaboration enables iterative design-make-test-analyze cycles where NMX's biophysics and NMR expertise informs MFI's computational modeling, and MFI's virtual screening identifies compounds for NMX to experimentally verify. Structural data from NMX informs MFI's protein models for virtual library screening, accelerating confirmation of specific hypotheses.
• Université de Sherbrooke (Lead)flagshipStrategic or Co-development Partner · 13 December 2021NMX is collaborating with Université de Sherbrooke and 18 other private partners in the $13.85M FACS-funded project 'Le Consortium Acuité-QC: prédire et visualiser l'action du médicament'. NMX contributes custom biophysics strategies to complement the AI/ML-enhanced drug discovery platform being developed for Quebec's life sciences ecosystem.
• Institute for Research in Immunology and Cancer (IRIC) - Université de MontrealcoreStrategic or Co-development Partner · 13 December 2021Public collaborator in the FACS-funded provincial drug discovery platform project, contributing to the decentralized public-private platform enhanced by AI and machine learning.
• Centre Armand-Frappier Santé Biotechnologie - INRScoreStrategic or Co-development Partner · 13 December 2021Public collaborator in the FACS-funded provincial drug discovery platform project focused on sustainable and decentralized drug discovery technologies.
• Centre Hospitalier Universitaire Sainte-JustinecoreStrategic or Co-development Partner · 13 December 2021Public collaborator in the FACS-funded provincial drug discovery platform project.
• Mila Research InstitutecoreStrategic or Co-development Partner · 13 December 2021AI research institute collaborating on the FACS-funded project to develop innovative technologies enhanced by artificial intelligence and machine learning for drug discovery.
• IRICoRminorStrategic or Co-development Partner · 13 December 2021Supporting partner in the FACS-funded provincial drug discovery platform project.
• AdMare BioInnovationsminorStrategic or Co-development Partner · 13 December 2021Supporting partner providing commercialization expertise for the FACS-funded provincial drug discovery platform.
• Sherbrooke InnopoleminorStrategic or Co-development Partner · 13 December 2021Regional innovation support partner for the FACS-funded drug discovery platform project.
• Steven LaPlante's laboratory at INRS - Université du QuébeccoreStrategic or Co-development PartnerJoint post-doctoral position in biophysics focused on discovering leads for future drugs using novel fragment-based lead discovery strategies targeting various diseases. Bridges academic research with pharmaceutical industry applications.
• La PresseminorOthersFeatured in La Presse portfolio article discussing NMX's role in helping biotech and pharma companies in early-stage drug discovery, highlighting interdisciplinary collaborations with institutions like Harvard Medical School.
• Harvard Medical SchoolcoreStrategic or Co-development PartnerAcademic institution engaged in ongoing collaborative partnerships with NMX, contributing to cutting-edge biotechnology research in Quebec.
• INRS - Université de QuébeccoreStrategic or Co-development PartnerLong-standing academic collaborator on multiple projects including COVID-19 drug research, HRas inhibitor studies, and biophysics method development.
• Remix TherapeuticscoreStrategic or Co-development PartnerCollaborated on spliceosome research published in Science and Nature Reviews, with NMX biochemistry team contributing recombinant U1snRNP production and protein characterization.
• University of MinnesotacoreStrategic or Co-development PartnerAcademic collaborator on histidine kinase inhibitor research published in Bioorganic Chemistry, exploring antibiotic resistance strategies through anti-virulence effects.
• The Broad InstitutecoreStrategic or Co-development PartnerCollaborator on histidine kinase inhibitor characterization research, contributing to antibiotic resistance studies.
• 3 Point BiominorStrategic or Co-development PartnerIndustry collaborator on the histidine kinase inhibitor research project.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Sygnature Discovery: UK-based CRO providing fragment-based drug discovery, biophysics, NMR, medicinal chemistry and computational chemistry to pharma/biotech; directly comparable to NMX in FBLD service offering and target customer segment.
• Domainex: Integrated drug discovery CRO offering biophysics, fragment screening, medicinal chemistry and computational chemistry; comparable to NMX as a mid-size CRO with similar FBLD/biophysics focus on biotech and pharma clients.
• Peak Proteins: UK CRO offering protein production, biophysics and structural biology services to drug discovery clients; directly comparable to NMX's target production and biophysics service lines serving biotech/pharma customers.
• Molecular Forecaster Inc. Computational chemistry and virtual screening firm partnered with NMX; comparable as a peer offering computational drug design services to the same biotech/pharma customers, with overlapping FBLD workflow integration.

Others

• Bruker BioSpin: Leading manufacturer of NMR spectrometers used by NMX; comparable as an adjacent/ecosystem player whose installed base and service contracts define the market NMX sells into.

Emerging players

• Schrödinger: Computational chemistry and structure-based drug design platform with growing biophysics services; partially overlaps with NMX's computational chemistry and FBLD offering but emphasizes in silico over wet-lab NMR.
• Beacon Discovery (now part of Eurofins): Specialized FBLD/biophysics CRO focused on fragment screening and structure-based drug design; directly comparable to NMX's FBLD platform and curated library offering for biotech and pharma discovery teams.

Broad incumbents

• Eurofins Discovery: Offers fragment screening, biophysics, and in vitro pharmacology services within Eurofins' global scientific services portfolio; comparable to NMX as a broad incumbent providing fragment-based and biophysical discovery capabilities to pharma/biotech.
• Charles River Laboratories: Large CRO offering biophysical screening, structural biology, NMR, and early-stage drug discovery services; a broad incumbent comparable to NMX but with significantly greater scale and a much broader service portfolio.
• Evotec: Global CRO and drug discovery platform offering fragment-based screening, biophysics, structural biology, and integrated drug discovery services to pharma; comparable to NMX as a broader incumbent in the same discovery services category, though much larger and risk-sharing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/nmx_research
• LinkedInlinkedin.com/company/nmx-research-and-solutions-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NMX Research & Solutions